Daratumumab injection is used alone or in combination with other medicines to treat multiple myeloma (a kind of bone marrow cancer). It is used alone in patients who have received at least three prior treatments that did not work well, including a proteasome inhibitor and an immunomodulatory agent, or who didn’t respond to both a proteasome inhibitor as well as an immunomodulatory agent.

Daratumumab injection is also used in combination with lenalidomide and dexamethasone to treat patients with newly diagnosed multiple myeloma who can’t receive autologous stem cell transplant and patients with relapsed (cancer that has come back) or refractory (cancer that didn’t respond to treatment) multiple myeloma who have received at least one previous treatment.

Daratumumab injection is also used in combination with bortezomib, melphalan, and prednisone to treat patients with newly diagnosed multiple myeloma who cannot receive an autologous stem cell transplant.

Daratumumab injection is also used in combination with bortezomib, thalidomide, and dexamethasone to treat patients with newly diagnosed multiple myeloma who could receive an autologous stem cell transplant.

Daratumumab injection is also used in combination with bortezomib and dexamethasone to treat patients with multiple myeloma who have received at least one prior treatment.

Daratumumab injection is also used in combination with carfilzomib and dexamethasone to treat patients with relapsed (cancer that has come back) or refractory (cancer that didn’t respond to treatment) multiple myeloma who have received one to three preceding treatments.

Daratumumab injection is also used in combination with pomalidomide and dexamethasone to treat patients with multiple myeloma who have received at least 2 treatments (including lenalidomide and a proteasome inhibitor).

This medication should only be administered by or under the supervision of a doctor.

The product is available in the following dosing forms:

1. Solution